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Abstract
Background: Deletions on the distal portion of the long arm of chromosome 6 are relatively uncommon, and only
a small number occurs in the paternal copy, causing growth abnormalities. As a result, extensive clinical
descriptions are lacking.
Case presentation: We describe a male of Italian descent born at 35 weeks by elective caesarean delivery presenting
hypoplastic left colon, bilateral inguinal hernia, dysplastic tricuspid and pulmonary valves, premature ventricular
contractions, recurrent otitis media, poor feeding, gastro-oesophageal reflux, bilateral pseudopapilledema, and
astigmatism. He also showed particular facial dysmorphisms and postnatal growth failure. Early psychomotor
development was mildly delayed. At 3.75 years, he was evaluated for severe short stature (−2.98 SD) and delayed bone
age. He showed an insulin-like growth factor 1 concentration (IGF-1) in the low-normal range. Growth hormone
stimulation tests showed a low response to clonidine and insulin. Magnetic resonance imaging showed hypophyseal
hypoplasia. Genetic evaluation by Single Nucleotide Polymorphism arrays showed a de novo 6q24.2-q25.2 deletion on
paternal chromosome 6.
Conclusion: We confirm that this is a new congenital malformation syndrome associated with a deletion of 6q24.2-q25.2
on paternal chromosome 6. We suggest evaluating the growth hormone axis in children with 6q24.2-q25.2 deletions and
growth failure.
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Background
Interstitial and terminal deletions of the long arm of
chromosome 6 have been known since 1975 [1] and are
relatively uncommon disorders. Just over 100 cases have
been reported to date [2–10].
The variability of size and location of specific deletions
and the lack of molecular mapping of breakpoints have
made it difficult to establish genotype–phenotype corre-
lations [11], even though 6q25 is a preferential location
for breakpoints in the 6q terminal deletions [11, 12].
With one notable exception [13], all patients experi-
enced mild to moderate intellectual disability [14]. In
addition, deletions involving band 6q25 have a high
(63 %) incidence of intrauterine growth retardation
(IUGR) [5]. Cryptorchidism appears to be common in
patients with middle and terminal deletions [4, 5].
Kumar et al. [13], and Nowaczyk et al. [14] reported
six children with de novo, paternal, interstitial deletions
involving the 6q24.3 region; one of these children was a
subject of a previous publication [13]. Some patients had
strikingly similar facial features, significant IUGR and
postnatal growth retardation with early developmental
delay [13, 14]. The third patient had IUGR and normal
development [13], which started a debate about whether
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a new congenital malformation syndrome was identified
[13]. While their growth rate may not coincide with a
growth chart, there is limited evidence of the causes of
growth delay in these children.
We describe herein a new case of de novo 6q24.2-q25.2
deletion on paternal chromosome 6 with growth hormone
(GH) deficiency. We evaluated the association between
the deletion and the patient’s symptoms and followed up
with recombinant human growth hormone (rhGH) treat-
ment. Finally, we compared previously published cases
with deletions overlapping our patient’s (Table 1) using
the Decipher database [15].
Case presentation
The propositus was the third child of healthy, non-
consanguineous Italian parents. The mother was 165 cm
and had menarche at 12 years of age. The father was
172 cm and had a normal pubertal development. The
target height was 175 cm ± 6 cm (−0.32 SDS). Two
sisters of the propositus were growing in the target
range.
The patient was born by elective cesarean delivery to a
29-year-old gravida after normal conception and 35 weeks
of gestation. The foetus was suspected of IUGR from the
27th week. His birth weight was 1740 g (−1.6 SDS), length
was 43.5 cm (−1.1 SDS), and head circumference was
32.2 cm (0.0 SDS). The child’s Apgar score was 7I-9V.
Prenatal ultrasounds also showed apparent cardiomeg-
aly, which was not confirmed postnatally. Following am-
niocentesis, the karyotype was found to be 46,XY.
Microsatellite analysis of chromosomes 2, 11, and 16
showed biparental inheritance, excluding uniparental pa-
ternal disomy.
As a newborn, the propositus was hospitalized for
hypoplastic left colon, which caused constipation in the
first few months of life.
Early psychomotor development was mildly delayed.
He rolled over at 5 months, sat alone and pulled to
stand at 10 months, said his first words at 18 months,
walked alone at 19 months, and said 25 single words at
2 years of age, but used no sentences.
He was referred for genetic evaluation at age 13.5 months
because of his poor growth. His medical problems included
dysplastic tricuspid and pulmonary valves with mild regur-
gitation, mitral valve prolapse, chronic otitis media, poor
feeding, and gastro-oesophageal reflux. Ophthalmoscopic
examination showed bilateral pseudopapilledema and
hyperopic astigmatism. He showed a relative macrocrania
with particular facial features such as prominent forehead,
epicanthic folds, upslanting palpebral fissures, large ears
and broad nasal bridge (Table 1, Fig. 1). At 2 years of age,
he underwent a bilateral inguinal herniotomy.
At 3 years 9 months of age, his height was 88.2 cm
(−2.98 SDS), his weight was 11.500 Kg (−3.34 SDS), his
body mass index (BMI) was 14.78 (−0.81 SDS), and his
occipitofrontal circumference was 50 cm (0.33 SDS)
(Fig. 2). A bone age evaluation revealed a 28-month
delay. Extensive biochemical and metabolic examina-
tions did not reveal abnormalities. The patient showed
only slight hyperthyreotropinemia (TSH 5.49 mIU/L;
normal range: 0.61–4.0 mIU/L). The plasma concentra-
tions of insulin-like growth factor 1 (IGF-1) and IGF
binding protein-3 (IGFBP-3) were in the lower part of
the normal range: 58 ng/ml (normal range 44–221 ng/
ml) and 1.4 μg/ml (normal range 1.0–4.7 μg/ml) for
IGF-1 and IGFBP-3, respectively.
At 5 years 8 months of age, his height was 96 cm (−3.66
SDS), his weight was 13.500 kg (−3.67 SDS), and his BMI
was 14.65 (−0.91) (Fig. 2). A blood examination confirmed
slight hyperthyreotropinemia (TSH 5.1 mIU/L) with
normal FT4. The plasma concentrations of IGF-1 and
IGFBP-3 were in the lower part of the normal range for
age and sex: 63 ng/ml (normal range: 54–228 ng/ml) and
1.3 μg/ml (normal range: 1.3–5.6 μg/ml) for IGF-1 and
IGFBP-3, respectively.
At 6 yrs of age, an echocardiogram showed a bicuspid
aortic valve. A magnetic resonance imaging (MRI) scan of
the brain showed peritrigonal T2 white matter hyperinten-
sity, in the absence of midline anomalies or anatomic
defects of the central nervous system. The hypothalamic-
hypophyseal region also showed pituitary hypoplasia with a
cyst in the pars intermedia. Neuropsychological evaluation
showed that deficits persisted, particularly in auditory-
language association, auditory pattern recognition, and
interhemispheric integration.
Because of the persistent and severe growth failure,
the child was evaluated with GH stimulation tests, which
showed a low response after clonidine (GH peaked at
4.46 μg/l) and insulin (GH peaked at 3.14 μg/l) tests.
Consequently, GH therapy (0.23 mg/kg/wk) was started.
The child experienced a good response to GH therapy
(Fig. 2). At 7 years 7 months of age, his height was
113.5 cm (−2.20 SDS), his weight was 19.800 kg (−1.81
SDS), his BMI was 15.37 (−0.66 SDS), and his Tanner
pubertal development stages were at G1 (genital develop-
ment), PH1 (pubic hair), and AH1 (auxiliary hair), with a
bilateral testicular volume of 2.5 ml.
His pubertal development started normally: at 11 years
4 months, his height was 137.6 cm (−1.27 SDS), his weight
was 31.000 kg (−1.38 SDS), his BMI was 16.4 (−1.04 SDS),
and his pubertal staging was: testicular volume of 5–6 ml
bilaterally, PH2, and AH2 (Fig. 2). The patient showed
asymmetry in his body proportion, with a 1.30 ratio
between the upper and lower segment.
Genetic analysis
Molecular karyotyping was also performed by array-CGH
on the proband’s DNA using an Agilent 180 K array
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6q breakpoints q23-q25 q23.3-24.2 q24.2-q25.1 q25.1-q25.3 q25.1-q26 q24.3-ter q25-1-q25.3 q25.1-25.3 q24.3-25.2 q24.3-q25.1 q25.1-q25.3 q25.1-q25.3 q24.2-q25.2 13
Parent of origin NA father NA NA NA NA NA NA NA NA father father father 4/4
Sex (M:F) M F M M M M M F M F M F M 9/4
Age (yrs.months) <0.1 3.0 1.0 17 <0.1 0.4 0.7 6.6 2.6 8.2 1.3 1.4 1.-1 -
IUGR/low birth weight + + + - - + + - - - + + + 8/13
Postnatal growth failure + + + - + + + + - + + + + 11/13
Microcephaly + - + + + + + NA - - - - - 7/12
Prominent forehead - - + + - - - + + - + + + 7/12
Epicanthic folds + +/− + + - + + + - - - - + 8/13
Downslanting palpebral fissures - - - + - + - - - +/− - - - 4/13
Upslanting palpebral fissures - - - - - - + + - - + + + 5/13
Retinal, macular abnormalities - ND - - + ND ND ND - ND - - - 1/8
Large ears - NA - + - + NA - - - - - + 3/11
Malformed ears - NA - + + + + + - + + + - 8/12
Broad nasal bridge - + + - - + + - + - - - + 6/13
Micrognathia + - - + - + + - - - - - - 4/13
Abnormal philtrum - - - - - - - - + +/− - - - 2/13
Microstomia + - NA NA NA NA + - + - - - - 3/9
Thin lips - + + - - NA NA + - + + + - 6/11
Congenital heart defect +°° - +§§ - - +d - +’ - +§ +° +& + 8/13
Respiratory distress - - + - + + NA - - + - + - 5/12
Feeding problems - + - + - - . - + + - - + 5/12
Cryptorchidism - + - + + - + - 4/8
Genital hypoplasia - NA NA NA - NA - - NA NA - - - 0/7
Short neck + + - - - + + NA - - - - - 4/12
Chest and trunk asymmetry - NA - + - + - NA - NA - + - 3/10
Spine abnormalities + ND - - - ND ND ND - ND - - - 1/8
Foot abnormalities - NA - + + + - - - + NA NA + 5/10
Abnormal hands, fingers + NA - + - + + - - + + NA + 7/11
Joint laxity - NA - - - NA NA NA + NA NA NA + 2/6












Table 1 Review of main phenotypic characteristics of patients with deletions overlapping 6q24.2-q25.2 (Continued)
Skin abnormalities + NA - - - NA NA NA + NA NA NA - 2/6
Seizures - - - + - + . - - - - - + 3/13
MRI/TC abnormalities ND ND ND - +a +b ND ND ND - - - +c 3/7
Developmental delay NA - + + NA + + + - + + + + 9/11
Other +1, 2 +1 +3
NA not available, ND Not determinable
aAgenesis of corpus callosum and temporal and occipital enlargement; bagenesis of corpus callosum; cpituitary hypoplasia with a cyst in the pars intermedia; dventricular septal defect and patent ductus arteriosus;
‘ventricular septal defect; °dysplastic tricuspid and pulmonary valves, premature ventricular contractions; °°systolic murmur without echocardiographic evaluation; +§§tricuspid regurgitation; +1Imperforate anus;
+2sacrum lipoma; +3hypoplastic left colon and inguinal hernia
+& secundum atrial septal defect












platform with a resolution of approximately 40 kb. Based
on the physical mapping positions of the Feb 2009 Assem-
bly (GRCh37/hg19) of the UCSC Genome Browser, this
analysis showed a deletion of approximately 10,741 Mbp
that involved the 6q24.2q25.2 region, with the breakpoint
falling between 143,297,976 bp (first deleted oligomer)
and 154,039,064 bp (last deleted oligomer) (Fig. 3a).
However, genetic evaluation by single nucleotide poly-
morphism (SNP) arrays (GeneChip Human Mapping
500 k, Affymetrix) showed a deletion of 11 Mb within the
6q24.2-q25.2 region on paternally inherited chromosome
6 (Fig. 3b). Short Tandem Repeat (STR) analysis demon-
strated that the deletion occurred on the paternal 6
chromosome (Fig. 4; see supplement). Paternal sample
analysis excluded a balanced insertional translocation.
Discussion
We described a patient with interstitial deletion of the
chromosomal region 6q24.2-q25.2 on paternal chromo-
some 6, consistent with the observations of Kumar et al.
[13] and Nowaczyk et al. [14], who also found a paternal
deletion.
Interstitial and terminal deletions of chromosome 6q
are rare disorders, commonly associated with intellectual
disability, dysmorphic features, growth failure, and med-
ical complications [2, 5, 11].
Paternal interstitial deletions at 6q24.2-q25.2 are rarely
described, but some patients can share significant IUGR
and postnatal growth retardation, redundant skin, joint
laxity, and strikingly similar facial features, associated with
early developmental delay [13, 14]. We propose a new
congenital malformation syndrome associated with 6q24.2-
q25.2 on paternal chromosome 6 [14]. Other patients
showed IUGR but developed normally postnatally [13].
Our case report strongly suggests that an impairment
of the GH-IGF-1 axis is a possible cause of short stature
in this syndrome. Therefore, these patients should be
tested for GH secretion.
Interestingly, Nowaczyk et al. reported that one in three
patients with paternal deletion of 6q24.3 showed reduced
IGF-1 and IGFBP-3 secretion but subnormal GH secre-
tion after GH provocative testing (11.2 and 6.3 ng/ml,
respectively) [14]. In this patient, an MRI scan of the brain
appeared normal [14]. However, a trial of rhGH therapy
was started at age 3.0 years, as his height was 4.0 SD
below average, and an excellent response was experienced,
increasing height to 1.4 SD below average [14]. The
response to GH treatment was good in our patient,
Fig. 1 Anteroposterior view of the patient at 12 months of age
Fig. 2 Growth charts of the patient. The arrows indicate the onset of
growth hormone therapy and the target height (TH)
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showing that GH treatment could also be considered to
improve the prognosis with respect to stature in patients
with 6q24.2-q25.2 paternal interstitial deletions. Neverthe-
less, further studies are required to confirm the character-
istics of the GH-IGF-1 axis in these patients.
A 6q24.3 deletion of paternal origin is frequently
found with PLAG1 (Pleomorphic Adenoma Gene 1;
OMIM *603044) or ZAC1 (the zinc finger gene involved
in apoptosis), a gene member of the network of coregu-
lated genes comprising other imprinted genes involved
Fig. 3 Single Nucleotide Polymorphism (SNP) arrays (Fig. 3a) and array CGH with high resolution (Fig. 3b) showing a de novo deletion of
11Mb 6q24.2-q25.2
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in the control of embryonic growth [16]. PLAGL1 is an
imprinted gene, paternally expressed. Generally, in mouse
inactivation of the maternally repressed Plagl1 transcrip-
tion factor results in intrauterine growth restriction,
altered bone formation, and neonatal lethality [16]. This
aspect is very interesting, because patients with paternal
deletions of 6q24.2-q25.2 showed IUGR, early develop-
mental delay, and a typical facial appearance, suggesting
that the genetic basis for this syndrome is located within
the deleted 1 Mb region. Nevertheless, recent data seem
to suggest that methylation of PLAGL1 may be associated
with foetal and post-natal weight and BMI but not with
length [17].
Our 6q24.2-25.2 deletion partially overlaps those reported
in Decipher [15], which spare from 3,61 Mb to 8,52 Mb. In
nine reported cases (four males and four females and one
case with unknown chromosomal sex) the age, at initial
presentation, varies from <1 to 8 years (median age 4 years)
and growth delay/short stature is a constant reported
feature of the phenotype. The deletion is defined de novo in
one female case, but parent of origin is not determined; the
inheritance is unknown in other three cases, while in two
males is inherited from a non specified parent. Interestingly
in three male cases the deletion is also present and consti-
tutional in their fathers, two of which are referred with
similar phenotype to child, i.e. short stature or growth
delay, delayed speech and language development. In our
case the deletion has occurred on paternal chromosome 6.
In some patients, PLAGL1 gene is not included in the
deletions, while in other patients with more centromeric 6q
deletions, comprising PLAGL1 gene, growth impairment is
not described as a clinical feature. Anyway the role of this
gene in human growth process, remains to be elucidated.
Growth deviations are a common complication in
imprinting disorders. Imprinted genes are not bi-allelically
expressed, and diseases arise when an individual inherits
two copies of a chromosome that contains imprinted genes
from one parent (uniparental disomy) [18].
Nevertheless, our patient also showed pituitary hypopla-
sia as a possible cause of GH deficiency. In fact, some
patients with 6q deletions may show congenital midline
abnormalities, such as undescended testicles or very small
genitalia, heart defects (ventricular septal defects, atrioven-
tricular canal, atrial septal defect, tetralogy of Fallot, etc.),
imperforate anus, diaphragmatic hernia, cleft palate, and
umbilical hernia [6].
Conclusions
In conclusion, we report a child with a remarkable facial
features, a history of IUGR and postnatal growth failure
due to GH deficiency, disproportionate short stature, and
minimal developmental delay associated with a 6q24.3
deletion of paternal origin. For the first time, we report the
presence of GH deficiency and a long-term follow-up,
hypothesizing that dysregulation of the GH-IGF-1 axis may
be a frequent characteristic of this syndrome. Therefore, we
suggest evaluating the GH axis in children with 6q24.3
deletions and growth failure. Identification of imprinted
genes or further defining the expression of genes in the
Fig. 4 Short Tandem Repeat (STR) analysis demonstrated that deletion occurred on paternal chromosome 6. M =mother; P = proband; F = father
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region of deletion may lead to the identification of specific
genes important in the regulation of growth.
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